Notice: This company has been marked as potentially delisted and may not be actively trading. Proteon Therapeutics (PRTO) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends PRTO vs. CMPX, RGNX, ATYR, PROK, PRME, ENGN, CADL, ITOS, CRDF, and NMRAShould you be buying Proteon Therapeutics stock or one of its competitors? The main competitors of Proteon Therapeutics include Compass Therapeutics (CMPX), REGENXBIO (RGNX), Atyr PHARMA (ATYR), ProKidney (PROK), Prime Medicine (PRME), enGene (ENGN), Candel Therapeutics (CADL), iTeos Therapeutics (ITOS), Cardiff Oncology (CRDF), and Neumora Therapeutics (NMRA). These companies are all part of the "medical" sector. Proteon Therapeutics vs. Compass Therapeutics REGENXBIO Atyr PHARMA ProKidney Prime Medicine enGene Candel Therapeutics iTeos Therapeutics Cardiff Oncology Neumora Therapeutics Proteon Therapeutics (NASDAQ:PRTO) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, community ranking, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends. Does the MarketBeat Community favor PRTO or CMPX? Proteon Therapeutics received 235 more outperform votes than Compass Therapeutics when rated by MarketBeat users. However, 77.08% of users gave Compass Therapeutics an outperform vote while only 69.21% of users gave Proteon Therapeutics an outperform vote. CompanyUnderperformOutperformProteon TherapeuticsOutperform Votes27269.21% Underperform Votes12130.79% Compass TherapeuticsOutperform Votes3777.08% Underperform Votes1122.92% Do analysts rate PRTO or CMPX? Compass Therapeutics has a consensus target price of $11.38, indicating a potential upside of 353.19%. Given Compass Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Compass Therapeutics is more favorable than Proteon Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Proteon Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Compass Therapeutics 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78 Which has higher earnings and valuation, PRTO or CMPX? Proteon Therapeutics has higher earnings, but lower revenue than Compass Therapeutics. Compass Therapeutics is trading at a lower price-to-earnings ratio than Proteon Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProteon TherapeuticsN/AN/A-$20.73M-$1.15-3.57Compass Therapeutics$850K408.34-$42.49M-$0.37-6.78 Is PRTO or CMPX more profitable? Proteon Therapeutics' return on equity of 0.00% beat Compass Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Proteon TherapeuticsN/A N/A -118.68% Compass Therapeutics N/A -32.37%-30.67% Which has more risk & volatility, PRTO or CMPX? Proteon Therapeutics has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500. Comparatively, Compass Therapeutics has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500. Do insiders and institutionals have more ownership in PRTO or CMPX? 23.0% of Proteon Therapeutics shares are held by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are held by institutional investors. 45.7% of Proteon Therapeutics shares are held by insiders. Comparatively, 28.5% of Compass Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media favor PRTO or CMPX? In the previous week, Compass Therapeutics had 3 more articles in the media than Proteon Therapeutics. MarketBeat recorded 3 mentions for Compass Therapeutics and 0 mentions for Proteon Therapeutics. Compass Therapeutics' average media sentiment score of 1.25 beat Proteon Therapeutics' score of 0.00 indicating that Compass Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Proteon Therapeutics Neutral Compass Therapeutics Positive SummaryCompass Therapeutics beats Proteon Therapeutics on 11 of the 16 factors compared between the two stocks. Remove Ads Get Proteon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRTO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRTO vs. The Competition Export to ExcelMetricProteon TherapeuticsBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$90.93M$3.07B$5.64B$8.08BDividend YieldN/A1.47%4.89%4.04%P/E Ratio-3.5727.6723.7319.00Price / SalesN/A374.75381.75120.61Price / CashN/A168.6838.0534.64Price / Book-68.333.466.904.26Net Income-$20.73M-$71.72M$3.18B$247.00M Proteon Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRTOProteon TherapeuticsN/A$4.10+9.3%N/A+5.0%$90.93MN/A-3.5717Gap UpCMPXCompass Therapeutics3.6529 of 5 stars$2.37-11.9%$11.38+380.0%+26.5%$327.73M$850,000.00-6.4120RGNXREGENXBIO4.0515 of 5 stars$6.01-5.2%$33.88+463.6%-73.3%$297.77M$84.33M-1.19370ATYRAtyr PHARMA2.472 of 5 stars$3.10-8.8%$18.60+500.0%N/A$285.40M$235,000.00-3.3053Upcoming EarningsShort Interest ↑News CoveragePROKProKidney1.9881 of 5 stars$0.98-7.0%$5.00+412.0%-35.7%$284.84MN/A-1.783Positive NewsGap DownPRMEPrime Medicine3.0843 of 5 stars$2.08-13.3%$13.13+531.0%-76.3%$272.82M$2.98M-1.01234Earnings ReportENGNenGene3.8369 of 5 stars$5.24-0.2%$25.89+394.1%-68.8%$267.12MN/A-9.0331Analyst ForecastShort Interest ↓News CoverageCADLCandel Therapeutics3.4958 of 5 stars$8.20-0.7%$21.00+156.1%+376.8%$266.30M$120,000.00-4.7460Positive NewsGap UpITOSiTeos Therapeutics3.3873 of 5 stars$6.95-1.4%$25.75+270.5%-40.8%$265.45M$35M-2.2190Earnings ReportShort Interest ↓Analyst RevisionCRDFCardiff Oncology1.8842 of 5 stars$3.84-0.5%$11.67+203.8%-11.4%$255.45M$683,000.00-4.0920Positive NewsGap UpNMRANeumora Therapeutics3.2449 of 5 stars$1.34-10.1%$10.14+656.9%-92.1%$241.35MN/A-0.72108Earnings ReportAnalyst Downgrade Remove Ads Related Companies and Tools Related Companies Compass Therapeutics Alternatives REGENXBIO Alternatives Atyr PHARMA Alternatives ProKidney Alternatives Prime Medicine Alternatives enGene Alternatives Candel Therapeutics Alternatives iTeos Therapeutics Alternatives Cardiff Oncology Alternatives Neumora Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRTO) was last updated on 3/12/2025 by MarketBeat.com Staff From Our PartnersAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredWarning: What they're not telling you about these recent selloffsIn light of massive recent selloffs... our senior analyst Dan Ferris has issued a new warning for the American...Stansberry Research | SponsoredSilent Raid on IRAs and 401(k)s Begins—Are You Next?Look around—everything feels oddly steady. Gas prices aren't skyrocketing. Banks aren't collapsing. The mar...Genesis Gold Group | SponsoredMagnificent 7 wipeout: What's next?A massive wave of volatility is sweeping the stock market... After the recent selloff, the "Magnificent Sev...Chaikin Analytics | SponsoredWarren Buffet Just Made a $334 Billion BetDebt is out of control. Inflation is creeping back. And a major market downturn could be right around the corn...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Proteon Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Proteon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PRTO Stock Alerts